Item 7.01. Regulation FD Disclosure

On February 5, 2013, Protalix BioTherapeutics, Inc. (the "Company") issued a press release confirming, in response to inquiries received the morning of the release and a report appearing in the Israeli press, that the Company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that the Company will undertake any such strategic alternative.

A copy of the press release is furnished as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.